MTD
Mettler-Toledo International Inc.
MTD's fundamentals are strong: it turned 21% of its revenue into free cash flow and revenue grew 6.5%. At 38x earnings, it's trading in line with its usual 36x. Analysts expect earnings growth.
MTD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
MTD's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
MTD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 31x | $1,406 | -19% |
| Forward | 34x | $1,731 | — |
| Fair | 36x | $1,655 | -4.4% |
| Current | 38x | $1,731 | — |
| Expensive | 46x | $2,122 | +23% |
Historical ranges are pointers, not guarantees.
MTD's PE is in its fair range at 38x. If earnings grow as analysts expect, today's price would be 34x next year's earnings.
MTD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for MTD, with profitability improving.
MTD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $51.52 | +12% |
| Q3 2026 | $46.08 | +15% |
| Q2 2026 | $44.36 | +12% |
| Q1 2026 | $42.57 | +6.3% |
| Q4 2025 | $42.05 | +3.9% |
| Q3 2025 | $40.05 | +8% |
| Q2 2025 | $39.44 | +8.5% |
| Q1 2025 | $40.05 | +12% |
| Q4 2024 | $40.48 | +13% |
MTD's earnings per share have climbed steadily: $46.08 over the past year, up 15% from the year before, and higher year over year for eight quarters in a row.
MTD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +6.3% |
| Q2 2026 | $1B | +4.5% |
| Q1 2026 | $947.1M | +7.2% |
| Q4 2025 | $1.1B | +8.1% |
| Q3 2025 | $1B | +7.9% |
| Q2 2025 | $983.2M | +3.9% |
| Q1 2025 | $883.7M | -4.6% |
| Q4 2024 | $1B | +12% |
MTD's revenue has grown year over year for six quarters in a row: $1.1B last quarter, up 6.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 27% | +1.3 points |
| Q2 2026 | 28% | +2.9 points |
| Q1 2026 | 22% | -0.7 points |
| Q4 2025 | 29% | -1 points |
| Q3 2025 | 26% | -1 points |
| Q2 2025 | 25% | -0.4 points |
| Q1 2025 | 23% | -1 points |
| Q4 2024 | 30% | +5.2 points |
MTD's operating margin was 27% last quarter, up 1.3 points from the same quarter a year ago.
MTD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $281.5M | +2.4% |
| Q2 2026 | $282.6M | +33% |
| Q1 2026 | $122.4M | -31% |
| Q4 2025 | $184.1M | -18% |
| Q3 2025 | $274.9M | +18% |
| Q2 2025 | $212.5M | -9.1% |
| Q1 2025 | $177.2M | +2.7% |
| Q4 2024 | $224.9M | -9.7% |
MTD's free cash flow has been positive every quarter for six years: $871M over the past year, down 2.1% from the year before.
MTD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -148K shares |
| 1 year | -2.7% | -552K shares |
| 3 years | -8.5% | -1.9M shares |
| 5 years | -14% | -3.4M shares |
| Available history | -19% | -4.6M shares |
MTD has 20M diluted shares, down 2.7% from a year ago, with $782M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $226.2M |
| Q2 2026 | $206.3M |
| Q1 2026 | $206.3M |
| Q4 2025 | $143.7M |
| Q3 2025 | $218.7M |
| Q2 2025 | $218.7M |
| Q1 2025 | $218.7M |
| Q4 2024 | $212.5M |
MTD spent $782M buying back its own shares over the past year, down 9.9% from the year before.
MTD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.7x | Healthy |
| Q4 2024 | 1.8x | Healthy |
MTD's net debt is about 1.6 years of its operating earnings (EBITDA), down from 1.9 years a year ago.
MTD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.7 | Overbought |
| Stochastic | 86.2 | Overbought |
MTD's weekly RSI is 74 (overbought) and its Stochastic is 86 (overbought).
MTD PE vs Healthcare Sector
| Metric | MTD | Sector median | Relative |
|---|---|---|---|
| PE | 38x | 26x | 45% above |
| PE % | 58 | 29 | 29 pts above |
MTD is trading at 38x earnings, a 45% premium to the Healthcare sector's median of 26x.
MTD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,621.0 | 6.8% above |
| 20 week MA | $1,465.0 | 18% above |
| 50 week MA | $1,359.5 | 27% above |
| 100 week MA | $1,302.9 | 33% above |
| 200 week MA | $1,308.6 | 32% above |
MTD has climbed back above all five of its weekly moving averages, and it's now 32% above its 200-week average.
MTD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $792.8 | $1,140.2 | +44% |
| 2021 | $1,140.2 | $1,626.2 | +43% |
| 2022 | $1,626.2 | $1,439.1 | -12% |
| 2023 | $1,439.1 | $1,213.0 | -16% |
| 2024 | $1,213.0 | $1,234.2 | +1.8% |
| 2025 | $1,234.2 | $1,420.1 | +15% |
| 2026 YTD | $1,420.1 | $1,730.9 | +22% |
MTD has finished higher in four of the last six years. It's up 22% so far in 2026.